Compare Colgate-Palmolive Company (CL) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Colgate-Palmolive Company vs Cassava Sciences Inc — how do they compare? Colgate-Palmolive Company trades at $90.95 (market cap $74.59B), while Cassava Sciences Inc trades at $1.09 (market cap $56.04M). The key difference: Colgate-Palmolive Company is far larger — about 1331× Cassava Sciences Inc's market cap, and Colgate-Palmolive Company pays a 2.27% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| CL | FLNA | |
|---|---|---|
Market Cap | $74.59B | $56.04M |
Sector | Consumer Staples | Health |
52-Week High | $99.14 | $4.64 |
52-Week Low | $74.98 | $1.09 |
Enterprise Value | $81.22B | -$30.54M |
Dividend Yield | 2.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Colgate-Palmolive (CL) trades at $93.21, up 1.05% with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with 60.06% gross margins and 822.05% ROE, though valuation metrics appear elevated with a P/E of 36.13. Recent dividend declarations and positive analyst coverage (42% buy rating) support the defensive stock's appeal amid market rotation into stable cash flow names.
Outlook remains positive with a $97 consensus price target representing 4% upside, though premium valuation and North American segment softness present headwinds. The company's 64-year dividend growth streak and global diversification provide stability, while inflation pressures and competitive threats require monitoring for sustained outperformance.
FLNA trades at $1.15, down 2.54% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company continues to report losses, with a net income of -$90.97M in 2025 and negative cash flow, though it has beaten EPS estimates for the last three quarters. Recent news highlights ongoing development in its TSC-related epilepsy therapies.
Despite consistent earnings beats, FLNA's negative profitability and cash burn pose significant risks. Analyst sentiment is positive with a 66.7% buy rating, but the stock's outlook depends heavily on clinical success and future funding. Investors should weigh the high-risk, high-reward nature of this biotech play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Colgate-Palmolive Company
Since its founding in 1806, Colgate-Palmolive has grown to become a leading global consumer product company. In addition to its namesake oral care line, the firm manufactures shampoos, shower gels, deodorants, and home care products that are sold in over 200 countries (international sales account for about 70% of its consolidated total, including approximately 45% from emerging regions). It also owns specialty pet food maker Hill's, which sells its products through veterinarians and specialty pet retailers.
Read more on CL →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
